


Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Attorney Docket Number	251266				

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Document Number	Kind Code			
	AA	US- 5,238,951		08-24-1993	Sher	
	AB	US- 5,650,415		07-22-1997	Tang et al.	
	AC	US- 5,747,498		05-05-1998	Schnur et al.	
	AD	US- 5,770,599		06-23-1998	Gibson	
	AE	US- 5,962,458		10-05-1999	Lohmann et al.	
	AF	US- 6,071,921		06-06-2000	Lohmann et al.	
	AG	US- 6,103,728		08-15-2000	Tang et al.	
	AH	US- 6,126,917		10-03-2000	Mishani et al.	
	AI	US- 6,184,225		02-06-2001	Thomas et al.	
	AJ	US- 6,204,267		03-20-2001	Tang et al.	
	AK	US- 6,235,746		05-22-2001	Davis et al.	
	AL	US- 6,288,082		09-11-2001	Wissner et al.	
	AM	US- 6,294,532		09-25-2001	Thomas et al.	
	AN	US- 6,337,335		01-08-2002	Hutchings et al.	
	AO	US- 6,344,455		02-05-2002	Bridges et al.	
	AP	US- 6,344,459		02-05-2002	Bridges et al.	
	AQ	US- 6,358,962		03-19-2002	Uckun et al.	
	AR	US- 6,362,336		03-26-2002	Lohmann et al.	
	AS	US- 6,391,874		05-21-2002	Cockerill et al.	
	AT	US- 6,403,580		06-11-2002	Himmelsbach et al.	
	AU	US- 6,414,148		07-02-2002	Thomas et al.	
	AV	US- 6,432,406		08-13-2002	Goldberg et al.	
	AW	US- 6,469,013		10-22-2002	Uckun et al.	
	AX	US- 6,472,391		10-29-2002	Matsumo et al.	

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/573,336
Filing Date	September 18, 2006
First Named Inventor	BANNEN, Lynne Canne
Group Art Unit	
Examiner Name	
Attorney Docket Number	251266

Sheet 2 of 19

U.S. PATENT DOCUMENTS


Examiner Initials ¹	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Document Number	Kind Code			
	AY	US- 6,476,031		11-05-2002	Chakravarty et al.	
	AZ	US- 6,476,040		11-05-2002	Norris et al.	
	BA	US- 6,495,556		12-17-2002	Uckun et al.	
	BB	US- 6,514,971		02-04-2003	Thomas et al.	
	BC	US- 6,521,618		02-18-2003	Boschelli et al.	
	BD	US- 6,521,629		02-18-2003	Fox	
	BE	US- 6,525,046		02-25-2003	Cirillo et al.	
	BF	US- 6,552,027		04-22-2003	Uckun et al.	
	BG	US- 6,562,818		05-13-2003	Bridges	
	BH	US- 6,593,333		07-15-2003	Cumming	
	BI	US- 6,602,863		08-05-2003	Bridges et al.	
	BJ	US- 6,608,048		08-19-2003	Tsou et al.	
	BK	US- 6,608,071		08-19-2003	Altmann et al.	
	BL	US- 6,627,634		09-30-2003	Himmelsbach et al.	
	BM	US- 6,630,489		10-07-2003	Crawley	
	BN	US- 6,642,242		11-04-2003	Collis et al.	
	BO	US- 6,649,620		11-18-2003	Collis et al.	
	BP	US- 6,653,305		11-25-2003	Himmelsbach et al.	
	BQ	US- 6,656,946		12-02-2003	Himmelsbach et al.	
	BR	US- 6,664,390		12-16-2003	Barth et al.	
	BS	US- 6,673,803		01-06-2004	Thomas et al.	
	BT	US- 6,723,726		04-20-2004	Cockerill et al.	
	BU	US- 6,727,256		04-27-2004	Carter et al.	
	BV	US- 6,734,303		05-11-2004	Ahman et al.	

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/09A/B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
				Examiner Name	
Sheet	3	of	19	Attorney Docket Number	251266

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Document Number	Kind Code			
	BW	US- 6,740,651		05-25-2004	Himmelsbach et al.	
	BX	US- 6,759,410		07-06-2004	Adams et al.	
	BY	US- 6,809,097		10-26-2004	Thomas et al.	
	BZ	US- 2002/0032208	A1	03-14-2002	Lohmann et al.	
	CA	US- 2002/0049197	A1	04-25-2002	Himmelsbach et al.	
	CB	US- 2002/0137757	A1	09-26-2002	Uckun et al.	
	CC	US- 2002/0161010	A1	10-31-2002	Chakravarty et al.	
	CD	US- 2002/0161226	A1	10-31-2002	Uckun et al.	
	CE	US- 2002/0165243	A1	11-07-2002	Uckun et al.	
	CF	US- 2002/0169165	A1	11-14-2002	Kath et al.	
	CG	US- 2002/0169180	A1	11-14-2002	Himmelsbach et al.	
	CH	US- 2002/0173509	A1	11-21-2002	Himmelsbach et al.	
	CI	US- 2002/0173646	A1	11-21-2002	Thomas et al.	
	CJ	US- 2002/0177600	A1	11-28-2002	Griffin et al.	
	CK	US- 2002/0177601	A1	11-28-2002	Himmelsbach et al.	
	CL	US- 2003/0013728	A1	01-16-2003	Uckun et al.	
	CM	US- 2003/0018029	A1	01-23-2003	Barker et al.	
	CN	US- 2003/0045525	A1	03-06-2003	Collis et al.	
	CO	US- 2003/0045537	A1	03-06-2003	Lee et al.	
	CP	US- 2003/0065180	A1	04-03-2003	Tsou et al.	
	CQ	US- 2003/0069230	A1	04-10-2003	Becker et al.	
	CR	US- 2003/0069248	A1	04-10-2003	Chakravarty et al.	
	CS	US- 2003/0100753	A1	05-29-2003	Boulton et al.	
	CT	US- 2003/0149056	A1	08-07-2003	Wissner et al.	

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
				Examiner Name	
Sheet	4	of	19	Attorney Docket Number	251266

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No.	U.S. Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Document Number	Kind Code			
	CU	US- 2003/0149062	A1	08-07-2003	Jung et al.	
	CV	US- 2003/0153568	A1	08-14-2003	Kusack et al.	
	CW	US- 2003/0171386	A1	09-11-2003	Connell et al.	
	CX	US- 2003/0176451	A1	09-18-2003	Carter et al.	


FOREIGN PATENT DOCUMENTS									
Examiner Initials ¹	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided**	
		Office	Number	Kind Code				Yes	No
	CY	EP	0875506	B1	02-26-2003	Pfizer Limited			
	CZ	EP	0880508	B1	04-16-2003	AstraZeneca AB			
	DA	EP	0912570	B1	09-10-2003	Glaxo Group Limited			
	DB	EP	0973746	B1	09-24-2003	Wyeth Holdings Corp.			
	DC	EP	0977737	B1	09-17-2003	Janssen Pharmaceutica			
	DD	EP	1044969	A2	10-18-2000	Pfizer Products Inc.			
	DE	EP	1117653	A1	07-25-2001	AstraZeneca AB			
	DF	EP	1143950	B1	03-09-2005	BioEqual AG			
	DG	EP	1243582	A1	09-25-2002	Kirin Beer K. K.			
	DH	EP	1301440	B1	03-16-2005	CFPI NUFARM			+
	DI	EP	1304110	A	04-23-2003	Glaxo Group Limited			
	DJ	EP	1340748	A1	09-02-2003	Nippon Sinyaku Co.			
	DK	EP	1411046	A1	04-21-2004	Kirin Beer K. K.			
	DL	WO	95/15758	A	06-15-1995	Rhone-Poulenc Rorer			
	DM	WO	95/19774	A	07-27-1995	Warner-Lambert Co.			
	DN	WO	96/09294	A	03-28-1996	Wellcome Foundation			
	DO	WO	96/15118	A	05-23-1996	Zeneca Limited			

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
				Examiner Name	
Sheet	5	of	19	Attorney Docket Number	251266

FOREIGN PATENT DOCUMENTS									
Examiner Initials ¹	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided**	
		Office	Number	Kind Code				Yes	No
	DP	WO	96/40142	A	12-19-1996	Pfizer Inc.			
	DQ	WO	97/03069	A	01-30-1997	Glaxo Group Limited			
	DR	WO	97/17329	A	05-15-1997	Kirin Beer K. K.			+
	DS	WO	97/22596	A	06-26-1997	Zeneca Limited et al.			
	DT	WO	97/30035	A	08-21-1997	Zeneca Limited et al.			
	DU	WO	97/32856	A	09-12-1997	Zeneca Limited et al.			
	DV	WO	98/13350	A	04-02-1998	Zeneca Limited et al.			
	DW	WO	98/13354	A	04-02-1998	Zeneca Limited et al.			
	DX	WO	99/10349	A	03-04-1999	Zeneca Limited et al.			
	DY	WO	00/18761	A	04-06-2000	American Cyanamid			
	DZ	WO	00/20402	A	04-13-2000	Zeneca Limited			
	EA	WO	00/21955	A	04-20-2000	Zeneca Limited et al.			
	EB	WO	00/43366	A	07-27-2000	Kirin Beer K. K.			+
	EC	WO	00/47212	A	08-17-2000	AstraZeneca UK Ltd.			
	ED	WO	00/55141	A	09-21-2000	Boehringer Ingelheim			
	EE	WO	00/56338	A	09-28-2000	Parker Hughes Institute			
	EF	WO	00/56720	A	09-28-2000	Parker Hughes Institute			
	EG	WO	00/68201	A	11-16-2000	AstraZeneca AB			
	EH	WO	01/21596	A	03-29-2001	AstraZeneca AB			
	EI	WO	01/47890	A	07-05-2001	Kirin Beer K. K.			+
	EJ	WO	01/68186	A	09-20-2001	American Cyanamid			
	EK	WO	01/94341	A	12-13-2001	AstraZeneca UK Ltd.			
	EL	WO	02/00188	A	01-03-2002	Cognis France S.A.			+
	EM	WO	02/00649	A	01-03-2002	AstraZeneca AB			

- * A concise statement of relevance is being submitted in lieu of a translation, 37 CFR 1.98(a)(3).
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	251266
Sheet	6	of	19		


FOREIGN PATENT DOCUMENTS									
Examiner Initials ¹	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided**	
		Office	Number	Kind Code				Yes	No
	EN	WO	02/16352	A	02-28-2002	AstraZeneca AB et al.			
	EO	WO	02/18351	A	03-07-2002	Boehringer Ingelheim			+
	EP	WO	02/30924	A	04-18-2002	AstraZeneca AB et al.			
	EQ	WO	02/30926	A	04-18-2002	AstraZeneca AB et al.			
	ER	WO	02/34744	A	05-02-2002	AstraZeneca AB et al.			
	ES	WO	02/36570	A	05-10-2002	AstraZeneca AB et al.			
	ET	WO	02/44166	A	06-06-2002	AstraZeneca AB et al.			
	EU	WO	02/85895	A	10-31-2002	AstraZeneca AB et al.			
	EV	WO	02/088110	A	11-07-2002	Kirin Beer K. K.			+
	EW	WO	02/92571	A	11-21-2002	AstraZeneca AB			
	EX	WO	02/92577	A	11-21-2002	AstraZeneca AB et al.			
	EY	WO	02/92578	A	11-21-2002	AstraZeneca UK Ltd.			
	EZ	WO	02/92579	A	11-21-2002	AstraZeneca AB			
	FA	WO	03/000188	A	01-01-2003	Ariad Pharmaceuticals			
	FB	WO	03/000660	A	01-03-2003	Kirin Beer K. K.		X	
	FC	WO	03/037252	A	05-08-2003	Merck & Co., Inc.			
	FD	WO	03/040109	A	05-15-2003	AstraZeneca AB			
	FE	WO	03/045395	A	06-05-2003	AstraZeneca AB et al.			
	FF	WO	03/047584	A	06-12-2003	AstraZeneca AB et al.			
	FG	WO	03/048159	A	06-12-2003	AstraZeneca AB et al.			
	FH	WO	03/050108	A	06-19-2003	Pfizer Products, Inc.			
	FI	WO	03/053960	A	07-03-2003	AstraZeneca AB et al.			
	FJ	WO	03/055491	A	07-10-2003	AstraZeneca AB et al.			
	FK	WO	03/055492	A	07-10-2003	AstraZeneca AB			

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
				Examiner Name	
Sheet	7	of	19	Attorney Docket Number	251266

FOREIGN PATENT DOCUMENTS									
Examiner Initials ¹	Cite No.	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Translation Provided ²	
		Office	Number	Kind Code				Yes	No
	FL	WO	03/055866	A	07-10-2003	Bayer Corporation			
	FM	WO	03/064413	A	08-07-2003	AstraZeneca UK Ltd.			
	FN	WO	03/064421	A	08-07-2003	Glaxo Group Limited			
	FO	WO	03/064431	A	08-07-2003	Glaxo Group Limited			
	FP	WO	03/066060	A	08-14-2003	Boehringer Ingelheim			
	FQ	WO	03/082831	A	10-09-2003	AstraZeneca UK Ltd.			
	FR	WO	03/089439	A	10-30-2003	Boehringer Ingelheim			
	FS	WO	2004/035572	A	04-29-2004	Kirin Beer K. K.			+
	FT	WO	2004/041829	A	05-21-2004	AstraZeneca UK Ltd.			
	FU	WO	2004/054585	A	07-01-2004	Pfizer Products Inc.			
	FV	WO	2004/055003	A	07-01-2004	Neurogen Corporation			
	FW	WO	2004/058267	A	07-15-2004	Ariad Pharmaceuticals			
	FX	WO	2005/003140	A	01-13-2005	Pharmacia & Upjohn			
	FY	WO	2005/030140	A	04-07-2005	Exelixis, Inc.			

OTHER - NON PATENT LITERATURE DOCUMENTS


Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	FZ	ABOUNADER et al., "In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis," <i>FASEB J.</i> , 16 (1): 108-110 (January 2002).		
	GA	ABRAMS et al., "SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer," <i>Mol. Cancer Ther.</i> , 2: 471-478 (2003).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Attorney Docket Number	251266				
Sheet	8	of	19		

OTHER - NON PATENT LITERATURE DOCUMENTS


Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	GB	APPERLEY et al., "Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta," <i>N. Engl. J. Med.</i> , 347 (7): 481-487 (August 15, 2002).		
	GC	BEEBE et al., "Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy," <i>Cancer Res.</i> , 63: 7301-7309 (November 1, 2003).		
	GD	BEGHINI et al., "c-kit activating mutations and mast cell proliferation in human leukemia," <i>Blood</i> , 92 (2): 701-702 (1998).		
	GE	BEGHINI et al., "C-kit mutations in core binding factor leukemias," <i>Blood</i> , 95 (2): 726-727 (January 15, 2000).		
	GF	BELLO et al., "Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma," <i>Clin. Cancer Res.</i> , 10 (13): 4527-4537 (July 1, 2004).		
	GG	BERGE et al., "Pharmaceutical salts," <i>J. Pharm. Sci.</i> , 66 (1): 1-19 (January 1977).		
	GH	BERGSLAND et al., "Bevacizumab (BV) + chemotherapy (CT) may improve survival in metastatic colorectal cancer (MCRC) subjects with unfavorable prognostic indicators," <i>Proc. Am. Soc. Clin. Oncol.</i> , 20: Abstract 2247 (2001).		
	GI	BESMER et al., "A new acute transforming feline retrovirus and relationship of its oncogene <i>v-kit</i> with the protein kinase gene family," <i>Nature</i> , 320 (6061): 415-421 (April 3-9, 1986).		
	GJ	BIRCHMEIER et al., "Met, metastasis, motility and more," <i>Nat. Rev. Mol. Cell Biol.</i> , 4 (12): 915-925 (December 2003).		
	GK	BLACKLEDGE et al., "Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors," <i>Br. J. Cancer</i> , 90 (3): 566-572 (February 9, 2004).		
	GL	BLAGOSKLONNY, "STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon,'" <i>Leukemia</i> , 16: 570-572 (2002).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Attorney Docket Number	251266				

OTHER - NON PATENT LITERATURE DOCUMENTS


Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published	Translation Provided**	
			Yes	No
	GM	BLUME-JENSEN et al., "The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136," <i>Curr. Biol.</i> , 8 (13): 779-782 (June 18, 1998).		
	GN	BOLEN, "Nonreceptor tyrosine protein kinases," <i>Oncogene</i> , 8 (8): 2025-2031 (August 1993).		
	GO	BONASERA et al., "Potential ¹⁸ F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase," <i>Nucl. Med. Biol.</i> , 28 (4): 357-374 (2001).		
	GP	BOSCHELLI et al., "Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles," <i>J. Med. Chem.</i> , 44 (5): 822-833 (March 1, 2001).		
	GQ	BOTTARO et al., "Out of air is not out of action," <i>Nature</i> , 423: 593-595 (June 5, 2003).		
	GR	BROUDY et al., "Signaling via Src family kinases is required for normal internalization of the receptor c-Kit," <i>Blood</i> , 94 (6): 1979-1986 (September 15, 1999).		
	GS	BUTTERFIELD, "Response of severe systemic mastocytosis to interferon alpha," <i>Br. J. Dermatol.</i> , 138 (3): 489-495 (March 1998).		
	GT	CAO et al., "Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models," <i>Proc. Natl. Acad. Sci. USA</i> , 98 (13): 7443-7448 (June 19, 2001).		
	GU	CHIAN et al., "Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant," <i>Blood</i> , 98 (5): 1365-1373 (September 1, 2001).		
	GV	CHRISTENSEN et al., "A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes <i>in vitro</i> and exhibits cytoreductive antitumor activity <i>in vivo</i> ," <i>Cancer Res.</i> , 63: 7345-7355 (November 1, 2003).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/06A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Attorney Docket Number	251266				

Sheet	10	of	19
-------	----	----	----

OTHER - NON PATENT LITERATURE DOCUMENTS


Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	GW	CHRISTENSEN et al., "Characterization of selective c-Met inhibitors with cytotoxic activity against human tumor," <i>Proc. Am. Assoc. Cancer Res.</i> , 44 (2nd ed.): 932-933, Abstract 4963 (July 11-14, 2003).		
	GX	COHEN et al., "Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia," <i>Clin. Cancer Res.</i> , 8: 935-942 (May 2002).		
	GY	COOLS et al., "The FIP1L1-PDGFR α kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia," <i>Curr. Opin. Hematol.</i> , 11 (1): 51-57 (January 2004).		
	GZ	DAGHER et al., "Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors," <i>Clin. Cancer Res.</i> , 8: 2034-2038 (October 2002).		
	HA	DAI et al., "Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux," <i>J. Pharmacol. Exp. Ther.</i> , 304 (3): 1085-1092 (March 2003).		
	HB	DEMETRI et al., "Clinical activity and tolerability of the multi-targeted tyrosine kinase inhibitor SU11248 in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) refractory to imatinib mesylate," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22: 814, Abstract 3273 (2003).		
	HC	DREVS et al., "Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in two clinical phase I trials," <i>Proc. Am. Soc. Clin. Oncol.</i> , 21: 85a, Abstract 337 (2002).		
	HD	EISENBERG et al., "Pharmacotherapy of gastrointestinal stromal tumors," <i>Expert Opin. Pharmacother.</i> , 4 (6): 869-874 (June 2003).		
	HE	FERRARA et al., "The biology of VEGF and its receptors," <i>Nat. Med.</i> , 9 (6): 669-676 (June 2003).		
	HF	FOLLENZI et al., "Cross-talk between the proto-oncogenes <i>Met</i> and <i>Ron</i> ," <i>Oncogene</i> , 19 (27): 3041-3049 (2000).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Sheet	11	of	19	Attorney Docket Number	251266

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided ²	
			Yes	No
	HG	FUNAKOSHI et al., "Hepatocyte growth factor: from diagnosis to clinical applications," <i>Clin. Chem. Acta</i> , 327 (1-2): 1-23 (January 2003).		
	HH	FYFE et al., "Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22: Abstract 3617 (2004).		
	HI	GERRITSEN et al., "Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells," <i>Br. J. Pharmacol.</i> , 140 (4), 595-610 (October 2003).		
	HJ	GILLILAND et al., "Role of FLT3 in leukemia," <i>Curr. Opin. Hematol.</i> , 9 (4): 274-281 (July 2002).		
	HK	HEDRICK et al., "Post-progression therapy (PPT) effect on survival in AVF2107, a phase III trial of bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22: Abstract 3517 (2004).		
	HL	HEINRICH et al., "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor," <i>J. Clin. Oncol.</i> , 21 (23): 4342-4349 (December 1, 2003).		
	HM	HIROTA et al., "Gain-of-function mutations of <i>c-kit</i> in human gastrointestinal stromal tumors," <i>Science</i> , 279 (5350): 577-580 (January 23, 1998).		
	HN	HOLASH et al., "VEGF-Trap: A VEGF blocker with potent antitumor effects," <i>Proc. Natl. Acad. Sci. USA.</i> , 99 (17): 11393-11398 (August 20, 2002).		
	HO	HONGYO et al., "Specific <i>c-kit</i> mutations in sinonasal natural killer/t-cell lymphoma in China and Japan," <i>Cancer Res.</i> , 60: 2345-2347 (May 1, 2000).		
	HP	HU-LOWE et al., "Pharmacological activities of AG013736, a small molecule inhibitor of VEGF/PDGR receptor tyrosine kinases," <i>Proc. Am. Assoc. Cancer Res.</i> , 43: Abstract 5357 (March 2002).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Sheet	12	of	19	Attorney Docket Number	251266

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided ²	
			Yes	No
	HQ	INGRAM et al., "Genetic and biochemical evidence that haploinsufficiency of the <i>Nf1</i> tumor suppressor gene modulates melanocyte and mast cell fates in vivo," <i>J. Exp. Med.</i> , 191 (1): 181-187 (January 3, 2000).		
	HR	JO et al., "Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells," <i>J. Biol. Chem.</i> , 275 (12): 8806-8811 (March 24, 2000).		
	HS	JOHNSON et al., "Phase II study of STI571 (Gleevec TM) for patients with small cell lung cancer," <i>Proc. Am. Soc. Clin. Oncol.</i> , 21: Abstract 1171 (2002).		
	HT	KABBINAVAR et al., "Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22: Abstract 3516 (2004).		
	HU	KELLY et al., "CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)," <i>Cancer Cell</i> , 1 (5): 421-432 (June 2002).		
	HV	KIM, "Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model," <i>Clin. Cancer Res.</i> , 9: 5161-70 (November 1, 2003).		
	HW	KINDLER et al., "Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22: Abstract 4009 (2004)		
	HX	KISSEL, "Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses," <i>EMBO J.</i> , 19 (6): 1312-1326 (March 15, 2000).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/06A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Sheet	13	of	19	Attorney Docket Number	251266

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	HY	KIYOKAWA et al., "Overexpression of ERK, an EPH family receptor protein tyrosine kinase, in various human tumors," <i>Cancer Res.</i> , 54 (14): 3645-3650 (July 15, 1994).		
	HZ	KONG-BELTRAN et al., "The Sema domain of Met is necessary for receptor dimerization and activation," <i>Cancer Cell</i> , 6 (1): 75-84 (July 2004).		
	IA	KUBO et al., "Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase," <i>Bioorg. Med. Chem.</i> , 11 (23), 5117-5133 (November 17, 2003).		
	IB	LAIRD et al., "Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents," <i>Expert Opin. Investig. Drugs</i> , 12 (1): 51-64 (January 2003).		
	IC	LEHMANN et al., "IFN α treatment in systemic mastocytosis," <i>Ann. Hematol.</i> , 78 (10): 483-494 (October 1999).		
	ID	LENNARTSSON et al., "Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction," <i>Oncogene</i> , 18 (4): 5546-5553 (September 30, 1999).		
	IE	LEV et al., "A specific combination of substrates is involved in signal transduction by the kit-encoded receptor," <i>EMBO J.</i> , 10 (3): 647-654 (March 1991).		
	IF	LINDAHL et al., "Pericyte loss and microaneurysm formation in PDGF-B-deficient mice," <i>Science</i> , 277 (5323): 242-245 (July 11, 1997).		
	IG	LIOTTA et al., "The microenvironment of the tumour-host interface," <i>Nature</i> , 411: 375-379 (May 17, 2001).		
	IH	LONGATI et al., "Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene," <i>Curr Drug Targets</i> , 2 (1): 41-55 (March 2001).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/573,336
Filing Date	September 18, 2006
First Named Inventor	BANNEN, Lynne Canne
Group Art Unit	
Examiner Name	
Attorney Docket Number	251266

Sheet	14	of	19
-------	----	----	----

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	II	LONGLEY et al., "Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis," <i>Proc. Natl. Acad. Sci. USA</i> , 96 (4): 1609-1614 (February 16, 1999).		
	IJ	LYNCH et al., "Neurofibromatosis I," <i>Neurol. Clin. N. Am.</i> , 20 (3): 841-865 (August 2002).		
	IK	MA et al., "c-Met: Structure, functions and potential for therapeutic inhibition," <i>Cancer Metastasis Rev.</i> , 22 (4): 309-325 (2003).		
	IL	MA et al., "c-MET mutational analysis in small cell lung cancer," <i>Cancer Res.</i> , 63: 6272-6281 (October 1, 2003).		
	IM	MAHER, "Malignant glioma: genetics and biology of a grave matter," <i>Genes Dev.</i> , 15: 1311-1333 (2001).		
	IN	MAKI et al., "Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans," <i>Int. J. Cancer</i> , 100: 623-626 (2002).		
	IO	MARONE et al., "Treatment of mastocytosis: pharmacologic basis and current concepts," <i>Leuk. Res.</i> , 25 (7): 583-894 (July 2001).		
	IP	MASS et al., "Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22: Abstract 3616 (2004)		
	IQ	MATTER, "Tumor angiogenesis as a therapeutic target," <i>Drug Discov. Today</i> , 6 (19): 1005-1024 (October 1, 2001).		
	IR	MAULIK et al., "Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition," <i>Cytokine Growth Factor Rev.</i> , 13 (1): 41-59 (February 2002).		
	IS	MAULIK et al., "c-Met/HGF pathway inhibition through a novel tyrosine kinase inhibitor in small cell lung cancer," <i>Proc. Am. Assoc. Cancer Res.</i> , 44 (2nd ed.): 1238, Abstract 6200 (July 11-14, 2003).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Sheet	15	of	19	Attorney Docket Number	251266

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	IT	MENDEL et al., "In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship," <i>Clin. Cancer Res.</i> , 9: 327-337 (January 2003).		
	IU	MICHIELI et al., "Targeting the tumor and its microenvironment by a dual-function decoy Met receptor," <i>Cancer Cell</i> , 6 (1): 61-73 (July 2004).		
	IV	MIKNYOCZKI et al., "The TRK tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma," <i>Clin. Cancer Res.</i> , 5: 2205-2212 (August 1999).		
	IW	MORGAN et al., "Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies," <i>J. Clin. Oncol.</i> , 21 (21): 3955-3964 (November 2003).		
	IX	MOSS et al., "Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans," <i>J. Pharmacol Exp. Ther.</i> , 307 (2): 476-480 (2003).		
	IY	MUFTI et al., "Myelodysplastic syndrome," <i>American Society of Hematology Education Program Book</i> , 1: 176-199 (2003).		
	IZ	MURRAY et al., "SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model," <i>Clin. Exp. Metastasis</i> , 20 (8): 757-766 (December 2003).		
	JA	NATH et al., "Shedding of c-Met is regulated by crosstalk between a G-protein coupled receptor and the EGF receptor and is mediated by a TIMP-3 sensitive metalloproteinase," <i>J. Cell Sci.</i> , 114 (6): 1213-1220 (2001).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
				Examiner Name	
Sheet	16	of	19	Attorney Docket Number	251266

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	JB	O'FARRELL et al., "An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients," <i>Clin. Cancer Res.</i> , 9: 5465-5476 (November 15, 2003).		
	JC	O'FARRELL et al., "Analysis of biomarkers of SU11248 action in an exploratory study in patients with advanced malignancies," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22: 234, Abstract 939 (2003).		
	JD	OGITA et al., "Synthesis and structure-activity relationship of diarylamide urea derivatives as selective inhibitors of the proliferation of human coronary artery smooth muscle cells," <i>Bioorg. Med. Chem.</i> , 10 (6): 1865-1871 (June 2002).		
	JE	PAI, "Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors," <i>FASEB J.</i> , 17: 1640-1647 (2003).		
	JF	PENNACCHIETTI et al., "Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene," <i>Cancer Cell</i> , 3 (4): 347-361 (April 2003).		
	JG	PLOWMAN et al., "Receptor tyrosine kinases as targets for drug intervention," <i>Drug News Perspect.</i> , 7 (6): 334-339 (1994).		
	JH	PROPPER et al., "Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C," <i>J. Clin. Oncol.</i> , 19 (5): 1485-1492 (March 1, 2001).		
	JI	REILLY, "FLT3 and its role in the pathogenesis of acute myeloid leukaemia," <i>Leuk. Lymphoma</i> , 44 (1): 1-7 (January 2003).		
	JJ	RUBIN et al., "Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans," <i>J. Clin. Oncol.</i> , 20 (17): 3586-3591 (September 1, 2002).		
	JK	RUGGERI et al., "CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models," <i>Cancer Res.</i> , 63: 5978-5991 (September 15, 2003).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/08A/B (08-03)
Approved for use through 07/31/2008 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Attorney Docket Number	251266				
Sheet	17	of	19		

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided ²	
			Yes	No
	JL	RYAN et al., "Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis," <i>J. Neurosci. Res.</i> , 37 (3): 415-432 (February 15, 1994).		
	JM	SATTLER et al., "The novel small molecule drug SU-MI-2 induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase," <i>Proc. Am. Assoc. Cancer Res.</i> , 44 (2nd ed.): 202, Abstract 1005 (July 11-14, 2003).		
	JN	SAUCIER et al., "The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis," <i>Proc. Natl. Acad. Sci. USA</i> , 101 (8): 2345-2350 (February 24, 2004).		
	JO	SAWYERS, "Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia," <i>Cancer Cell</i> , 1 (5): 413-415 (June 2002).		
	JP	SHIMIZU et al., "The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB," <i>Cancer Res.</i> , 59: 3719-3723 (August 1, 1999).		
	JQ	SINGER et al., "Prognostic value of <i>KIT</i> mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors," <i>J. Clin. Oncol.</i> , 20 (18): 3898-3905 (September 2002).		
	JR	SMITH et al., "Single agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia," <i>Blood</i> , 103 (10): 3669-3676 (May 15, 2004).		
	JS	STABILE et al., "Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy," <i>Gene Ther.</i> , 11 (3): 325-335 (February 2004).		
	JT	SUI et al., "Synergistic activation of MAP kinase (ERK1/2) by erythropoietin and stem cell factor is essential for expanded erythropoiesis," <i>Blood</i> , 92 (4): 1149-1242 (August 15, 1998).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → +

PTO/SB/08A/B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
				Examiner Name	
Sheet	18	of	19	Attorney Docket Number	251266

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	JU	TAKAI et al., "Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer," <i>Oncol. Rep.</i> , 8 (3): 567-573 (May-June 2001).		
	JV	THOMAS et al., "Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer," <i>Proc. Am. Soc. Clin. Oncol.</i> , 20: Abstract 279 (2001).		
	JW	TIAN et al., "Activating c-kit gene mutations in human germ cell tumors," <i>Am. J. Pathol.</i> , 154 (6): 1643-1647 (June 1999).		
	JX	TIMOKHINA et al., "Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation," <i>EMBO J.</i> , 17 (21): 6250-6262 (November 2, 1998).		
	JY	TOMIOKA et al., "Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model," <i>Cancer Res.</i> , 61 (20): 7518-7524 (October 15, 2001).		
	JZ	TONER et al., "PET imaging study of SU11248 in patients with advanced malignancies," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22: Abstract 767 (2003).		
	KA	WASHINGTON et al., "The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in caucasian and Asian healthy subjects," <i>Proc. Am. Soc. Clin. Oncol.</i> , 22: Abstract 553 (2003).		
	KB	WEDGE et al., "ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration," <i>Cancer Res.</i> , 62: 4646-4655 (August 15, 2002).		
	KC	WEISBERG et al., "Inhibition of mutant FLT3 receptors in leukemia cells by small molecule tyrosine kinase inhibitor PKC412," <i>Cancer Cell</i> , 1: 433-443 (June 2002).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

* An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box →



PTO/SB/06A/B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/573,336
				Filing Date	September 18, 2006
				First Named Inventor	BANNEN, Lynne Canne
				Group Art Unit	
Examiner Name					
Sheet	19	of	19	Attorney Docket Number	251266

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Provided**	
			Yes	No
	KD	WOOD et al., "PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration," <i>Cancer Res.</i> , 60: 2178-2789 (April 15, 2000).		
	KE	WRIGHT et al., "Synthesis and hypotensive properties of new 4-aminoquinolines," <i>J. Med. Chem.</i> , 14 (11): 1060-1066 (November 1971).		
	KF	XIN et al., "Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo," <i>Am. J. Pathol.</i> , 158 (3): 1111-1120 (March 2001).		
	KG	YANG et al., "A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer," <i>Proc. Am. Soc. Clin. Oncol.</i> , 21: Abstract 15 (2002).		
	KH	YARDEN et al., "Untangling the ErbB signalling network," <i>Nat. Rev. Mol. Cell Biol.</i> , 2 (2): 127-137 (February 2001).		
	KI	YUNG et al., "A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma," <i>Proc. Am. Soc. Clin. Oncol.</i> , 21: Abstract 315 (2002).		
	KJ	ZHANG et al., "Modulation of tumor angiogenesis by stem cell factor," <i>Cancer Res.</i> , 60: 6757-6762 (December 1, 2000).		
	KK	ZHENG et al., "A chimeric Fab antibody serves as an antagonist to the HGF/SGF receptor cMet," <i>Proc. Am. Assoc. Cancer Res.</i> , 44 (2nd ed.): 1139, Abstract 5717 (July 11-14, 2003).		
	KL	ZHOU, "The Eph family receptors and ligands," <i>Pharmacol Ther.</i> , 77 (3): 151-181 (March 1998).		

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.